Type your tag names separated by a space and hit enter

Nonalcoholic Fatty Liver Disease (NAFLD)

Nonalcoholic Fatty Liver Disease (NAFLD) is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

  • A spectrum of fatty liver diseases not due to excess alcohol consumption ranging from nonalcoholic fatty liver (NAFL), to nonalcoholic steatohepatitis (NASH), to cirrhosis with hepatocyte injury with/without fibrosis
  • Leading cause of chronic liver disease; implicated in up to 90% of patients with asymptomatic, mild aminotransferase elevation not caused by alcohol, viral hepatitis, or medications

Description

  • NAFL (1)
    • Reversible condition in which large vacuoles of triglyceride fat accumulate in hepatocytes
    • Liver biopsy: fatty deposits in >30% of cells, no hepatocyte ballooning, no necrosis, no fibrosis
    • Alanine aminotransferase/aspartate aminotransferase (ALT/AST) enzymes usually normal but may be elevated, rarely >3 to 4 times ULN
    • Minimal risk of progressing to cirrhosis or liver failure
    • Synonym: steatosis
  • NASH: progressive form of NAFL (1)
    • Liver biopsy: fatty deposits in >50% of cells with ballooning, acute/chronic inflammation, ± fibrosis
    • ALT and AST elevated, generally <3 to 4 times ULN
    • May progress to cirrhosis, liver failure, and rarely hepatocellular cancer; 30% with NASH may progress to fibrosis over 5 years.
  • NASH cirrhosis (1)
    • Presence of cirrhosis with current or previous histologic evidence of steatosis or steatohepatitis

Epidemiology

  • NAFLD: most common chronic liver disease globally; usually benign, asymptomatic
  • Predicted to become the most frequent indication for liver transplantation by 2030 (2)
  • NASH may be symptomatic with progressive inflammation and fibrosis.
    • Predominant age: 40s to 50s; can occur in children
    • Predominant sex: male > female (slight)

Incidence
Estimates vary widely from 31 to 86 cases of NAFLD per 10,000 person-years to 29/100,000 person-years (1)

Prevalence
  • United States estimate: 30–40% (3)
  • Worldwide: 6–33%, median 20–25% (1)
  • Present in 58–74% of obese persons (BMI >30) and 90% of morbidly obese persons (BMI >39) (1)
  • Among individuals with T2DM, rate of 69–87%; in patients with dyslipidemia, rate of 50% (1)

Etiology and Pathophysiology

Primary mechanism is insulin resistance, which leads to increased lipolysis, triglyceride synthesis, and increased hepatic uptake of fatty acids.

  • NAFLD: excessive triglyceride accumulation in the liver and an impaired ability to remove fatty acids
  • NASH: “2-hit” hypothesis: (i) macrovesicular steatosis due to increased hepatic lipid synthesis, reduced transfer of lipids, and increased insulin resistance with hepatic oxidative stress and (ii) mitochondrial damage leading to impaired restoration of ADT stores, lipid peroxidation, and resultant inflammatory injury (1)
  • Other possible mechanism is lipotoxicity. Free-fatty acid metabolites cause endoplasmic reticular stress, hepatocyte apoptosis, necrosis, and inflammation. Hepatocellular injury triggers fibrogenesis and inflammation, hastening disease progression (3).

Genetics
Largely unknown: Some familial clustering and increased heritability. NAFL: more first-degree relatives with cirrhosis than matched controls; NASH: 18% with affected first-degree relative. Carriers of hemochromatosis gene are more likely to be affected. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M polymorphism may play a role in NAFLD, hypertriglyceridemia, and insulin resistance (1,2).

Risk Factors

  • Obesity (BMI >30), visceral obesity (waist circumference >102 cm for men or >88 cm for women), hypertension, dyslipidemia, high serum triglycerides and low serum high-density lipoprotein (HDL) levels, metabolic syndrome
  • Type 2 diabetes, cardiovascular disease, and chronic kidney disease (2)
  • Possible associations with hypothyroidism, hypopituitarism, hypogonadism, obstructive sleep apnea, pancreatoduodenal resection, osteoporosis, psoriasis, and polycystic ovary syndrome (2)
  • Increasing age associated with increased prevalence, severity, advanced fibrosis, and mortality
  • High fructose intake linked to intestinal dysbiosis and metabolic stress (4)
  • Protein–calorie malnutrition; total parenteral nutrition (TPN) >6 weeks
  • Severe weight loss (starvation, bariatric surgery)
  • Organic solvent exposure (e.g., chlorinated hydrocarbons, toluene); vinyl chloride; hypoglycin A
  • Gene for hemochromatosis/other conditions with increased iron stores
  • Smoking
  • Drugs: tetracycline, glucocorticoids, tamoxifen, methotrexate, valproic acid, fialuridine, many chemotherapy regimens, and nucleoside analogues
Pregnancy Considerations
Acute fatty liver of pregnancy: Rare but serious complication in 3rd trimester. 50% of cases are associated with preeclampsia.
  • Symptoms: nausea, vomiting, headache, fatigue, right upper quadrant or epigastric pain, jaundice
  • Elevated ALT and AST >300 IU/L but usually <1,000 IU/L; elevated bilirubin
  • Liver biopsy confirms diagnosis (do not delay treatment for biopsy).
  • Early recognition and prompt delivery is key.
  • Recurrence is rare.
Pediatric Considerations
  • Increasing prevalence of NAFLD among children parallels rise in pediatric obesity.
  • Reports of NAFLD as early as age 2 years and NASH-related cirrhosis as early as age 8 years
  • Treat with intensive lifestyle modification. Vitamin E may be of possible benefit.
  • Reye syndrome: fatty liver syndrome with encephalopathy usually following viral illness
    • Vomiting with dehydration
    • Confusion, progressive CNS damage
    • Hepatomegaly with extensive fatty vacuolization
    • Hypoglycemia
  • Etiology unknown; viral URIs and drugs (especially salicylates) have been implicated.
  • Mortality rate: 50%
  • Treat with mannitol, IV glucose, and FFP.

General Prevention

  • Avoid excess alcohol: ≤3 standard drinks/day (men); ≤2 standard drinks/day (women)
  • Maintain appropriate BMI.
  • Prevention and optimal management of diabetes
  • Avoid hepatotoxic medications.
  • HAV and HBV vaccination if not immune
  • Pneumococcal and annual influenza vaccinations

Commonly Associated Conditions

Central obesity; HTN; type 2 diabetes; insulin resistance; hyperlipidemia; preeclampsia in pregnancy; CVD and arrhythmias; hypothyroidism; hypogonadism; OSA (2)

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

Stephens, Mark B., et al., editors. "Nonalcoholic Fatty Liver Disease (NAFLD)." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816854/all/Nonalcoholic_Fatty_Liver_Disease__NAFLD_.
Nonalcoholic Fatty Liver Disease (NAFLD). In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816854/all/Nonalcoholic_Fatty_Liver_Disease__NAFLD_. Accessed April 25, 2019.
Nonalcoholic Fatty Liver Disease (NAFLD). (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816854/all/Nonalcoholic_Fatty_Liver_Disease__NAFLD_
Nonalcoholic Fatty Liver Disease (NAFLD) [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 April 25]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816854/all/Nonalcoholic_Fatty_Liver_Disease__NAFLD_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Nonalcoholic Fatty Liver Disease (NAFLD) ID - 816854 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816854/all/Nonalcoholic_Fatty_Liver_Disease__NAFLD_ PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -